Invectys

Invectys is a clinical-stage biotech developing cancer immunotherapies based on RNA and gene therapy platforms. The company's lead program, INVAC-1, is a telomerase-targeting therapeutic cancer vaccine that has progressed into Phase 2 clinical trials for various solid tumors. Founded on research from Institut Pasteur, Invectys leverages its expertise in antigen discovery and delivery to generate specific and durable anti-tumor immune responses. As a private company, it has secured funding from venture capital and strategic partnerships to advance its pipeline.

DNA-based immunotherapy platform targeting tumor-associated antigens, primarily telomerase (hTERT), designed to stimulate potent and specific cytotoxic T-cell responses.

Invectys competes in the crowded cancer vaccine and immunotherapy space against large-cap biopharma (e.g., Moderna, BioNTech, GSK) and numerous biotechs developing mRNA, peptide, and viral vector-based vaccines. Its differentiation hinges on the universality of the telomerase target and its DNA platform's potential safety and immunogenicity profile.